{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:18:58Z","timestamp":1783653538710,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases","award":["R01 AR064320"],"award-info":[{"award-number":["R01 AR064320"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.joca.2018.02.898","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:49:40Z","timestamp":1519984180000},"page":"641-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation"],"prefix":"10.1016","volume":"26","author":[{"given":"E.","family":"Losina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Usiskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-752X","authenticated-orcid":false,"given":"D.J.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Messier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2018.02.898_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7326\/0003-4819-154-4-201102150-00001","article-title":"Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans","volume":"154","author":"Losina","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joca.2018.02.898_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Lawrence","year":"2008","journal-title":"Part II. Arthritis Rheum"},{"key":"10.1016\/j.joca.2018.02.898_bib3","first-page":"1020","article-title":"Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis","volume":"27","author":"Pincus","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2018.02.898_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/acr.20170","article-title":"After patients are diagnosed with knee osteoarthritis, what do they do?","volume":"62","author":"Grindrod","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.joca.2018.02.898_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/rheumatology\/keh045","article-title":"The use of conventional and complementary treatments for knee osteoarthritis in the community","volume":"43","author":"Jordan","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.joca.2018.02.898_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/acr.22412","article-title":"Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty","volume":"67","author":"Losina","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.joca.2018.02.898_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpain.2006.02.013","article-title":"Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials","volume":"11","author":"Bjordal","year":"2007","journal-title":"Eur J Pain"},{"key":"10.1016\/j.joca.2018.02.898_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.38273.626655.63","article-title":"Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials","volume":"329","author":"Bjordal","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2018.02.898_bib9","first-page":"708","article-title":"Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis","volume":"22","author":"Scholes","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2018.02.898_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00045391-200007020-00004","article-title":"Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics","volume":"7","author":"Whelton","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.joca.2018.02.898_bib11","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1001\/archinternmed.2010.391","article-title":"The comparative safety of analgesics in older adults with arthritis","volume":"170","author":"Solomon","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2018.02.898_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","article-title":"Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use","volume":"85","author":"Tram\u00e8r","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.joca.2018.02.898_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.joca.2018.02.898_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2018.02.898_bib15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.joca.2018.02.898_bib16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2018.02.898_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1185\/030079904X17974","article-title":"Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration","volume":"21","author":"Schaefer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.joca.2018.02.898_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.11121","article-title":"The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis","volume":"49","author":"Maetzel","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2018.02.898_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40258-013-0031-3","article-title":"Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective","volume":"11","author":"Wielage","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.joca.2018.02.898_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.reuma.2013.11.009","article-title":"Efficiency of naproxen\/esomeprazole in association for osteoarthrosis treatment in Spain","volume":"10","author":"Capel","year":"2014","journal-title":"Reumatol Cl\u00ednica"},{"key":"10.1016\/j.joca.2018.02.898_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0091-7435(03)00179-8","article-title":"Associations between recommended levels of physical activity and health-related quality of life: findings from the 2001 Behavioral Risk Factor Surveillance System (BRFSS) survey","volume":"37","author":"Brown","year":"2003","journal-title":"Prev Med"},{"issue":"26","key":"10.1016\/j.joca.2018.02.898_bib22","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.joca.2018.02.898_bib23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.joca.2015.12.011","article-title":"Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration","volume":"24","author":"Losina","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2018.02.898_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.joca.2018.02.898_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jech.2004.028068","article-title":"Physical activity and health related quality of life among people with arthritis","volume":"59","author":"Abell","year":"2005","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.joca.2018.02.898_bib26","series-title":"Osteoarthritis Initiative (OAI)","year":"2013"},{"key":"10.1016\/j.joca.2018.02.898_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.joca.2018.02.898_bib28","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.joca.2016.01.135","article-title":"Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review","volume":"24","author":"Smith","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2018.02.898_bib29","first-page":"1357","article-title":"Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial","volume":"40","author":"Essex","year":"2012","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.joca.2018.02.898_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-9-41","article-title":"Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use","volume":"9","author":"Straube","year":"2009","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.joca.2018.02.898_bib31","first-page":"CD002296","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.joca.2018.02.898_bib32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","article-title":"Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial","volume":"74","author":"Bensen","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.joca.2018.02.898_bib33","series-title":"Medicaid drug price comparison: average sales price to average wholesale price","author":"Levinson","year":"2005"},{"key":"10.1016\/j.joca.2018.02.898_bib34","series-title":"Medicare Fee Schedules","year":"2012"},{"key":"10.1016\/j.joca.2018.02.898_bib35","series-title":"Consumer Price Index (CPI)","year":"2016"},{"key":"10.1016\/j.joca.2018.02.898_bib36","series-title":"The Use of Medicines in the United States: Review of 2010","author":"IMS Institute for Health Informatics","year":"2011"},{"key":"10.1016\/j.joca.2018.02.898_bib37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.22764","article-title":"Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?","volume":"57","author":"Rahme","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2018.02.898_bib38","first-page":"677","article-title":"A\u00a0cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model","volume":"17","author":"Brereton","year":"2014","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.joca.2018.02.898_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2018.02.898_bib40","series-title":"Medical Officer Review: Celebrex (celecoxib)","author":"United States Food and Drug Administration","year":"2000"},{"key":"10.1016\/j.joca.2018.02.898_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2018.02.898_bib42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2018.02.898_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0002-9343(96)00380-4","article-title":"Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: is advanced age a risk factor?","volume":"102","author":"Solomon","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.joca.2018.02.898_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","article-title":"OARSI guidelines for the non-surgical management of knee osteoarthritis","volume":"22","author":"McAlindon","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2018.02.898_bib45","series-title":"Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States, States, Counties, and Puerto Rico Common Wealth and Municipios: April 1, 2010 to\u00a0July 1, 2012","year":"2012"},{"key":"10.1016\/j.joca.2018.02.898_bib46","series-title":"2009-2010 National Health and Nutrition Examination Survey (NHANES) Data","author":"Centers for Disease Control and Prevention (CDC)","year":"2010"},{"key":"10.1016\/j.joca.2018.02.898_bib47","first-page":"119","article-title":"Risk adjustment of Medicare capitation payments using the CMS-HCC model","volume":"25","author":"Pope","year":"2004","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.joca.2018.02.898_bib48","series-title":"Medicare Current Beneficiary Survey","year":"2009"},{"issue":"4","key":"10.1016\/j.joca.2018.02.898_bib49","first-page":"CD002296","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458418310203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458418310203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:48:15Z","timestamp":1761018495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458418310203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1063458418310203"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2018.02.898","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2018.02.898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.","name":"copyright","label":"Copyright"}]}}